1. Protein Tyrosine Kinase/RTK
  2. SHP2


Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

SHP2 Related Products (73):

Cat. No. Product Name Effect Purity
  • HY-100388
    SHP099 Inhibitor
    SHP099 is a potent, selective, orally available SHP2 inhibitor with an IC50 of 70 nM[1].
  • HY-136173
    Batoprotafib Inhibitor 99.41%
    Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].
  • HY-116009
    RMC-4550 Inhibitor
    RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC50 of 0.583 nM.
  • HY-141523
    Vociprotafib Inhibitor 99.47%
    Vociprotafib (RMC-4630) is a SHP2 inhibitor, a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signaling pathway. Vociprotafib has antitumor activity[1][2].
  • HY-B0183
    Ellagic acid Inhibitor
    Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
  • HY-162476
    SHP2-IN-28 Inhibitor
    SHP2-IN-28 (Compound 7188-0011) is an inhibitor of SHP2 (IC50=54.31 μM). SHP2-IN-28 exerts its inhibitory effect by binding to the variable site of SHP2 with high selectivity[1].
  • HY-N12915
    SHP2-IN-29 Inhibitor
    SHP2-IN-29 (Compound 3) is a potent SHP2 inhibitor with an IC50 value of 0.18 μM. SHP2-IN-29 also has inhibitory activity against PTP1B and TCPTP, with IC50 values of 4.27 and 4.74 μM, respectively.
  • HY-158762
    TK-642 Inhibitor
    TK-642 is a highly active, selective, orally activity SHP2 inhibitor based on pyrazole and pyrazine (IC50=2.7 nmol/L). TK-642 can effectively inhibit the proliferation of esophageal carcinoma cells and induce cell apoptosis. TK-642 can be used in the study of esophageal cancer[1].
  • HY-100595
    Sodium stibogluconate Inhibitor
    Sodium stibogluconate (Stibogluconate trisodium nonahydrate) is a potent inhibitor of protein tyrosine phosphatase. Sodium stibogluconate inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.
  • HY-120159
    GS-493 Inhibitor
    GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity[1].
  • HY-137092
    IACS-13909 Inhibitor 99.97%
    IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers[1].
  • HY-155533
    YF704 Inhibitor
    YF704 (compound 4w) is a selective allosteric inhibitor of SHP2 (IC50=0.25 μM). YF704 shows antiproliferative activity and induces apoptosis in cancer cells. YF704 also downregulates Erk1/2 and Akt phosphorylation levels in cancer cells[1].
  • HY-134885
    RMC-0331 Inhibitor 98.96%
    RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction[1].
  • HY-121879
    SHP836 Inhibitor 99.39%
    SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2[1].
  • HY-157318
    PB17-026-01 Inhibitor
    PB17-026-01 is a potent SHP2 allosteric inhibitor and shows the highest inhibitory activity with an IC50 value of 38.9?nM. PB17-026-01 can be used for the research of tumor[1].
  • HY-153740
    PF-07284892 Inhibitor 99.63%
    PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC50 value of 21 nM. PF-07284892 decreases the expression of pERK[1][2].
  • HY-108944
    LYP-IN-1 Inhibitor 99.78%
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders[1]. LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-21336
    3-Azetidinemethanol hydrochloride Inhibitor
    3-Azetidinemethanol hydrochloride, a medical intermediate, can be used in the synthesis of SHP2 inhibitor[1].
  • HY-149607
    SHP2-IN-22 Inhibitor
    SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research[1].
  • HY-114460
    SHP2-IN-1 Inhibitor
    SHP2-IN-1 (compound 13) is an allergic inhibitor of SHP2 (PTPN11), with an IC50 of 3 nM.